

May 27, 2014



**Amarantus**  
BioScience

## **Amarantus to Present at the 3rd Annual Marcum MicroCap Conference**

SAN FRANCISCO, May 27, 2014 (GLOBE NEWSWIRE) -- Amaranthus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald E. Commissiong, President and CEO will present at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 at the Grand Hyatt Hotel in New York.

The Company's presentation is scheduled to begin at 10:30 AM EDT and will be available via a live webcast. To access the webcast, please go to <http://wsw.com/webcast/marcum2/ambs>.

There will be an opportunity for investors to meet one-on-one with management. Interested investors should contact our Investor Relations department at [ir@amarantus.com](mailto:ir@amarantus.com).

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than \$500 million in market capitalization. For more information or to register, please visit the conference website at <http://www.marcumllp.com/microcap>.

### **About Amaranthus**

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amaranthus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit [www.Amarantus.com](http://www.Amarantus.com), or connect with the Company on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

### **About Marcum LLP**

Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300

professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include [Marcum LLP](#); [Marcum Technology LLC](#); [Marcum Search LLC](#); [Marcum Financial Services LLC](#); [Marcum Bernstein & Pinchuk LLP](#); [MarcumBuchanan Associates LLC](#); and [Marcum Cronus Partners LLC](#). For more information, visit [www.marcumllp.com](http://www.marcumllp.com).

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Investor/Media Contacts  
Aimee Boutcher, Director of Investor Relations  
Amarantus Bioscience Holdings, Inc.  
408-737-2734 x 101  
[ir@amarantus.com](mailto:ir@amarantus.com)

Source: Amarantus BioScience Holdings, Inc.